A SCOTTISH bio-tech company has developed a novel next generation “liquid biopsy” technology device that could revolutionise the early diagnosis and monitoring of difficult to detect cancers.
BioCaptiva, a University of Edinburgh spin-out, has raised more than £1 million in seed funding from business angel investment syndicate, Archangels, and Scottish Enterprise, to help develop the technology.
To prepare the company for this next stage in its development, BioCaptiva has appointed Dr Frank Armstrong FRCPE as non-executive chairman and Dr Stephen Little as a non-executive director.
BioCaptiva has developed a medical device that captures cfDNA (circulating free DNA) from the blood of patients in much greater quantities than the current standard of a single blood draw can, overcoming a significant current limitation of cancer liquid biopsy testing. Named BioCollector, it works alongside a standard apheresis machine, filtering cfDNA from the patient’s blood system.
The BioCollector is based on a decade of research at the University of Edinburgh, led by Professor Tim Aitman, director of the Centre for Genomic and Experimental Medicine, and Professor Mark Bradley of the University’s School of Chemistry.
Prototypes indicate the potential to detect early-stage cancers in patients without the need for a surgical biopsy and promising new approaches for monitoring and detecting disease recurrence which is not currently possible. The seed investment will enable BioCaptiva to in-license the technology and carry out its first trials to prove its safe use in humans.
Jeremy Wheeler, CEO of BioCaptiva, said: “We are confident that this platform technology can make a significant impact in this important area.”
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereLast Updated:
Report this comment Cancel